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Abstract
Background: The Danish OPUS I trial randomized 547 patients with first-episode psychosis to a two-year early-
specialised assertive treatment programme (OPUS) versus standard treatment. The two years OPUS treatment had
significant positive effects on psychotic and negative symptoms, secondary substance abuse, treatment adherence,
lower dosage of antipsychotic medication, and a higher treatment satisfaction. However, three years after end of
the OPUS treatment, the positive clinical effects were not sustained, except that OPUS-treated patients were
significantly less likely to be institutionalised compared with standard-treated patients. The major objective of the
OPUS II trial is to evaluate the effects of five years of OPUS treatment versus two years of OPUS treatment.
Methods: The OPUS II trial is designed as a randomized, open label, parallel group trial with blinded outcome
assessment. Based on our sample size estimation, 400 patients treated in OPUS for two years will be randomized to
further three years of OPUS treatment versus standard treatment. The specialized assertive OPUS treatment consists of
three core elements: assertive community treatment, psycho-educational family treatment, and social skills training.
Discussion: It has been hypothesized that there is a critical period from onset up to five years, which represents a
window of opportunity where a long-term course can be influenced. Extending the specialized assertive OPUS
treatment up to five years may allow the beneficial effects to continue beyond the high-risk period, through
consolidation of improved social and functional outcome.
Trial registration: Clinical Trial.gov NCT00914238
Background
The yearly incidence of patients aged 18 to 35 years
with schizophrenia in Denmark in 2008 was approxi-
mately 800. The yearly incidence for patients of the
same age with other disorders in the schizophrenia
spectrum (F 21 - F 29, ICD -10 [1]) was almost 500.
Schizophrenia is a severe neurodevelopmental disorder
with complex neuronal and psychosocial pathogenesis.
The first psychotic break down is usually seen in adoles-
cence or early adulthood and has a serious impact on
young peoples’ lives through interference with their
social lives and work. Furthermore, patients with psy-
chosis often suffer from substance abuse, depression [2],
suicide [3], and are often associated with high rates of
violence and legal problems [4]. The direct cost of schi-
zophrenia in European countries has been estimated to
two percent of the national health expenditures [5], - a
similar order of magnitude to cancer or ischaemic heart
disease. Moreover, there are also huge indirect costs
to society in terms of suffering of relatives and lost
productivity [5].
The focus on first-episode psychosis arises because
converging evidence suggest that the underlying illness
process that affects biological, psychological, and social
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domains undergo major deterioration around the onset
phase of the illness [6-8]. Delayed detection and treat-
ment is a widespread problem and predicts poor clinical
outcome [9,8]. The association between longer periods
of untreated psychosis and poorer outcomes is firmly
established [8,9]. It is therefore of utmost importance to
identify possibilities for prevention and treatment. The
evidence base for the psychosocial treatment of psycho-
tic disorders is still underdeveloped [10]. Historically,
randomized clinical trials have been few in number and
uneven in quality [11]. There is an urgent need for large
investigator-initiated, independent, non-commercial
trials of complex interventions that can help us prevent
the invalidating and deteriorating course in many
patients.
The Danish OPUS I trial randomized 547 patients with
first-episode psychosis to a two-year specialised intensive
assertive treatment programme (OPUS) consisting of a
multimodal phase-specific treatment of first episode psy-
chosis versus standard treatment [12]. The results signifi-
cantly favoured the OPUS treatment [12], showing positive
effects on psychotic and negative symptoms, secondary
substance abuse, treatment adherence, lower dosage of
antipsychotic medication, and a higher treatment satisfac-
tion after two years of treatment. However, the five-years
follow up study, three years after patients from OPUS were
transferred to standard treatment, showed that most of the
positive clinical effects were not sustained [13]. This con-
curs with the British LEO trial [14,12], demonstrating that
specialised treatment for people with first-episode psycho-
sis is effective on psychotic and negative symptoms only as
long as the treatment continues.
It has been hypothesised that there is a critical period up
to five years after onset of psychotic illness, which repre-
sents a window of opportunity where the long-term course
can be influenced [6]. The objective of the present OPUS-II
trial is therefore to carry out a comparison of five-years ver-
sus two-years of specialised assertive intervention for first
episode psychosis. Our hypothesis is that extending the
specialised assertive intervention service up to five years
will allow the beneficial effects to continue beyond this
high-risk period, through consolidation of improved social
and functional outcomes. The trial will thereby provide
clinicians and planners of mental health services with the
needed evidence regarding the optimal duration of specia-
lised treatment of first-episode psychosis patients. The
cost-benefit of a specialised assertive intervention sustained




The study is designed as a randomized, open label,
parallel-group trial with blinded outcome assessment
(Figure 1). Given the nature of the question, patients
and health care providers cannot be kept blind to treat-
ment allocation. There are five OPUS-teams in the
Capital Region and one OPUS-team in Central Denmark
Region.
Participants
All patients treated within the Danish mental health ser-
vices for at least 11/2 year by the six OPUS teams will be
approached for eligibility. Patients must fulfil the ICD 10
diagnostic criteria for schizophrenia or schizophrenia-like
psychosis (F2) [1].
Inclusion criteria
patients aged 18-37 years with first episode psychosis in
schizophrenia spectrum, who in the inclusion period of
the trials are treated for at least 11/2 year by one of the
six OPUS teams will be asked to give signed informed
consent to participate in the trial.
Exclusion criteria
patients whose diagnosis was evaluated retrospectively
and found not to fulfil the criteria for first-episode psy-
chosis in the F2-spectrum (ICD 10) at any time during
the first 11/2 year of OPUS treatment, and patients who
do not give signed informed consent to participate in
the trial. Drug and alcohol misuse will not lead to exclu-
sion. Patients who are mentally retarded in moderate to
severe degree are not treated in OPUS teams and are
therefore not a part of the inclusions and exclusions
criteria.
Randomization will take place approximately six months
prior to the termination of the original two-year OPUS
treatment. This will allow a gentle transfer to other treat-
ment services for the control group, and allow proper time
to plan the future course of treatment for the experimental
group. Expected duration of participating in the trial is
therefore 3 1/2 year from entry interview to follow-up
interview.
Randomisation
Randomisation will be centralised and computerised
with concealed randomisation sequence carried out by
the Copenhagen Trial Unit (CTU). Block size will be
unknown to the investigators and clinicians. Randomi-
sation will be stratified for treatment site (six sites)
and severity of global score on the four of the five
domains in SANS, anhedonia, avolition, alogia and
affective blunting, with distinction between at least one
of the global score measured less than 3 compared to
3 or more. Signed informed consent will be obtained
prior to patients being randomized. The allocations
concealment is ensured by the investigators call to
the randomisation unit, CTU, after completing the col-
lection of baseline data and data needed for the
randomisation.
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Interventions
The trial is pragmatic, comparing five years versus two
years of specialised, assertive intervention programme
(OPUS) defined by a set of protocols.
OPUS treatment
The integrated OPUS-treatment consists of three core
elements: assertive community treatment, psycho edu-
cational family treatment, and social skills training. In
addition, the patients receive group intervention to
facilitate recovery, cognitive behaviour therapy when
indicated, and crisis intervention. All patients are
designated a primary staff member, who are responsi-
ble for maintaining the contact and to coordinate the
treatment within the team, but also coordinate across
social services and other institutions involved in the
treatment. The pharmacological treatments are guided
by official Danish guidelines [15]. The team offers psy-
cho-educational family treatment, and will always try
to get in contact with at least one family member and
motivate the family to participate in a psycho-educa-
tional group. Patients will be visited in their homes or
other places in their community or at their primary
team member’s office according to the patient’s prefer-
ences. OPUS-treatment is tailored to meet the indivi-
dual patient’s needs.
The OPUS staff consists of a multidisciplinary team,
including a psychiatrist, psychologists, nurses, social
workers, physiotherapist, and vocational therapist. All
team members, except the psychiatrist, function as pri-
mary team member for the patients. The patient to
staff member ratio is 10:1. All members of the OPUS
staff are well educated, and have obtained great experi-
ence in first episode psychosis, and are continually
trained and supervised in the core elements of the
OPUS treatment to provide the specialised assertive
intervention.
Assessed for eligibility: all 
patients received OPUS 
Expect to be randomized:  
n = 400
Excluded:   
i Not meeting 
inclusion criteria 
i Declined to 
participate
Allocated to another three and a half 
year of OPUS treatment: n = 200 
Allocated to further half a year of 
OPUS treatment and then transfer to 
treatment as usual: n = 200 
All patients treated in OPUS for five 
years 
Patients treated in OPUS for two 
years + three years of treatment as 
usual, and participate in the OPUS II 
Analysed n = 
Excluded from analysis n = 
Give reasons n = 
Analysed n = 
Excluded from analysis n = 





















Figure 1 CONSORT diagram depicting flow of study participants in the OPUS II trial.
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The OPUS treatment in the experimental extension period
(year 2-5)
The aim is to continue the original patients - primary
team member relation in the extension period, if possi-
ble. Patient to staff member ratio is 15:1. Patients will
still be offered treatment tailored to meet their indivi-
dual needs. As a minimum the patients will receive at
least one face-to-face contact each month with their pri-
mary team member, and at least one other contact (e.g.,
telephone, mail). Families can in the extension period
still join the psycho-educational family treatment due to
their needs, and will at minimum be invited to booster
sessions of a survival skills workshop. Patients can parti-
cipate in all group programmes available in OPUS.
Within the resources of the team, there is no upper
limit for the amount of treatment the individual patient
may obtain.
The intensity of intervention will be registered. Inter-
ventions intensity will be extracted from the Danish
Psychiatric Case Register. In case of doubt, data will be
cross-validated with data extracted from the patient’s
medical record. Cost of intervention will be assessed
with help from the economists in regional health
authorities.
Standard treatment (year 2-5)
Patients, who after 11/2 years of OPUS treatment, are
randomized to further half a year of the specialised asser-
tive intervention, will be transferred to standard treat-
ment after a total of two years OPUS treatment. Standard
treatment can be either affiliation to a community mental
health centre, assertive community treatment, or primary
care, depending on the patient’s needs. The most com-
mon will be referral to community mental health care
centres, which usually offer the patient treatment in
which home visits are possible but office visits are the
general rule. The patient to staff member ratio varies
between 20:1 and 30:1.
The transition from the OPUS treatment to standard
treatment will be carried out gradually and as gentle as
possible.
Monitoring programme fidelity
Monitoring the fidelity of the intervention to OPUS
treatment will be carried out by an independent investi-
gator interviewing the six OPUS team leaders, using the
index of fidelity to Assertive Community Treatment
(IFACT) [16]. Assertive community treatment (ACT) and
the OPUS treatment have some key elements in com-
mon. However, the OPUS interventions are enhanced by
more specific content aimed at patients with first episode
psychosis, including better family involvement and social
skills training. To address these core elements we will
develop a programme fidelity measure with special regis-
tration of presence or absence of critical components in
the OPUS treatment. These elements are: primary con-
tact to one member of the team, psycho-education, crisis
plan, social skills training, rehabilitation support, psycho
educational family treatment, and multifamily group.
Outcome measures
The primary outcome measure is: negative symptoms
measured with schedule for assessment of negative
symptoms in schizophrenia (SANS [17]). Investigators at
entry and at the 31/2 years follow-up interview will be
independent and blinded for treatment allocation.
Through training interviews, we will ensure that the
assessors have a high level of interrater reliability with
kappa values for primary outcome measure of at least
0.70, prior to beginning the trial. We will also ensure
that assessors have an interclass correlation coefficient
(ICC) of at least 0.70 regarding SANS global scores. ICC
is calculated in SPSS using two-way mixed models for
absolute agreement on single measures.
The secondary outcome measures are: simultaneously
remission of both negative and psychotic symptoms, mea-
sured with SANS and schedule for assessment of positive
symptoms in schizophrenia (SAPS [17]), psychotic symp-
toms measured as continuous measures, substance abuse,
working alliance, self efficacy, user satisfaction, adherence
to treatment, compliance with medication, suicidal beha-
viour, use of bed days, ability to live independently, and
labour market affiliation. The criteria for remission are
that none of the global measures of severity in SAPS (glo-
bal scale for hallucinations, delusions, bizarre behaviour,
or thought disorder) and SANS (global scale for anhedo-
nia, avolition, alogia, and affective blunting) exceeds a
value of 2 (2 = mild symptoms). All outcome measures are
measured with validated scales (Table 1). These outcomes
will be assessed at baseline and at follow-up. Through
training interviews, we will also ensure that assessors have
an ICC coefficient of at least 0.70 regarding SAPS global
scores.
To be able to evaluate the external validity of the trial,
we will furthermore register sex, age, diagnosis, medical
treatment, substance abuse, and treatment adherence for
the patients who do not participate in the trial.
Register-based information
vital status, cause of death [18], use of mental health ser-
vices [19], living in an institution for mentally ill, living in
an institution for homeless, labour market affiliation, sick
leave, and early age pension will be extracted from the
unique, complete, longitudinal Danish registers [20]. Use
of antipsychotic medication will be extracted from the
Danish Register of Medicinal Product Statistic [21].
Participant withdrawal
participants can withdraw his/hers informed consent
from the trial at any time without any explanation.
We have obtained permission from the Danish Data
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Protection Agency (journal number: 2009-41-3314) for
register-based information for all randomized patients,
and in analyses of this information, we will include data
from all patients.
Sample size calculation
In the OPUS I trial we found that the patients treated in
OPUS had a mean score of 1.42 in negative dimension
and patients treated in standard treatment had a mean
score of 1.84 in negative dimension with standard devia-
tion of 1.2 [22,12]. In this present OPUS II trial we
want to be able to detect a difference of 0.4 point in
negative dimension, measured with SANS. We are thus
planning a trial of a continuous response variable from
independent control and experimental participants with
one control per experimental participant. If the true dif-
ference in the experimental and control means is 0.4
with a standard deviation of 1.2, we will need to study
142 experimental participants and 142 control partici-
pants to be able to reject the null hypothesis that the
population means of the experimental and control
groups are equal with probability (power) 0.80. The type
I error probability associated with this test of this null
hypothesis is 0.05, and 200 patients will be included in
each intervention group because we expect approxi-
mately 30% attrition.
Data analyses
The primary outcome measure, negative symptoms, will,
as other continuous outcome measures, be subjected to
analysis using a mixed-model analysis with a repeated
measurements model with unstructured variance matrix,
using the mixed-model command in SPSS. This approach
assumes that the distribution of missing data can be esti-
mated from the information from previous interviews and
from information about other patients in the database.
The condition for using this method is the assumption
that data are missing at random or missing completely at
random when taking into consideration the information
extracted from baseline interviews and information about
the other patients in the database. In this model, baseline
values of the scales are included. Variables included as
covariates will be site (six different teams), sex, co-morbid
substance abuse, baseline values of the remission variable,
and the baseline values of variables that differ significantly
in drop-out analyses. Besides the above-mentioned vari-
ables, compliance with medication, level of school educa-
tion, and whether or not a family member is involved in
treatment will be included in analyses of differences
between patients that are lost to follow-up and those who
remain in the trial. If significant, these variables will be
included as covariates.
For evaluation of the dichotomous secondary outcome
measure (simultaneously remission of psychotic and
negative symptoms or not), we will use multiple multi-
variate imputations, using all other covariates to impute
a distribution of missing values. The dichotomous out-
comes will be analysed with logistic regression analyses.
Variables included as covariates will be the same as
those included in analyses of continuous measures.
Similar to the repeated measurement, the condition for
using multiple imputations is that data are missing at
Table 1 Assessment instruments in the OPUS-II trial.
Topic: Instrument:
Psychopathology Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
[28],
Schedule for assessment of positive and negative symptoms
in schizophrenia (SAPS and SANS [17]) [29],
Hamilton’s depressions scale [30],
Suicidal behaviour,
DUP, Duration of Untreated Psychosis [31]
Social function Personal and Social Performance scale, PSP [32]
Global Assessment of Functioning, GAF [33]
Cognitive function Brief Assessment of Cognition in Schizophrenia, BACS [34]
Medication and side effect The UKU side effects rating scale, UKU [35]
Patients self rapport
Selfefficacy General Self - efficacy Scale [36]
Alliance Working Alliance Inventory, client, WAI [37]
Quality of life WHO Quality of Life, QOL [38]
Client satisfaction Client Satisfaction Questionnaire (CSQ) [39]
Vital status, cause of death [18], use of beddays [19] Danish national registers
Socio demographic information, labour market affiliation, civil status, cohabitation
status, children, education, living in an institution for mentally ill, living in an
institution for homeless [20]
Danish national registers
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random or missing completely at random, when taking
into consideration the information extracted from base-
line interviews and information about the other patients
in the database.
Analysis will be based on the intention-to-treat princi-
ple. Data from all patients will be included in the group
to which random assignment is made, regardless of
intervention received.
Feasibility
We plan to recruit 400 patients for the trial from 2009
to 2011. This is realistic as each of the six OPUS teams
discharges approximately 40 to 50 patients per year.
Ethical considerations
The result of this trial can be of great importance for
future health-care planning to benefit people with a first-
episode psychosis. The extended treatment period will, as
mentioned earlier, be tailored to meet the patient’s indi-
vidual needs, witch means monitoring the treatment
intensity up and down to support the patient’s empower-
ment and recovery process. The design of the trial does
not put participants at any unacceptable level of risk and
the trial design uses the best form of standard care as the
control group intervention.
Informed consent
All potential participants considered for this trial will be
provided with written and oral information on this trial
so that they can make an informed decision about their
participation. The participants must sign this consent
form before being randomized. This protocol was sub-
mitted the Regional Ethics Committees for The Capital
Region for review (journal no H-C-2009-035). The
Committee assessed the protocol to be exempt from
formal approval with the reason that the trial is a non-
biomedical trial. For further detail information please
contact: http://www.cvk.sum.dk
The participants will be offered written information
about the findings and the results after analysing the
OPUS II trial. The information is offered in form of a
standard letter and will be posted to those who sign up
for this opportunity.
The OPUS II trial has permission from the Danish
Data Protecting Agency: J. no. 2009-41-3314 and is pub-
licly registered (Clinical Trial Gov Identifier no.: NCT
00914238).
Discussion
The strengths of the OPUS II trial is the high internal
and external validity [23]. The use of a computer gener-
ated random sequence generation handled by an exter-
nal partner (the Copenhagen Trial Unit) reduces the
risk of selection bias. Secondly, the use of blinded out-
come assessors for the primary outcome and the use of
intention-to-treat analysis aim to prevent biased effect
estimate [23].
The publication of the current design article and
registration of the trial at ‘clinical.trials.gov’ are intended
to prevent selective outcome reporting. The risk of spur-
ious findings, random error, is reduced, in case the
pre-specified sample size is reached.
The fact that we are not able to blind the participants
and personnel in the extension period of OPUS treat-
ment might increase the risk of performance bias. Due
to the novelty and excitement of participating in a
research project it could be argued, that both partici-
pants and staff conducting the experimental intervention
would be more enthusiastic and keen to perform well
and thereby offer a higher level of OPUS treatment than
the actual intervention itself.
All potential patients in the catchments area are
approached and offered OPUS II treatment and together
with few exclusion criteria it provides a high level of
external validity. However, the educational requirements
for OPUS staff are a potential limitation to less devel-
oped health-care services.
Negative symptoms as measured with SANS are the
primary outcome measure for this trial. Negative symp-
toms are associated to the patients experience of quality
of life and the level of social functions [24,25], and
therefore is likely to have a great impact on peoples live
through interference with their social and educational
lives. Furthermore, negative symptoms have been shown
to have higher prognostic value than psychotic symp-
toms [26,27].
A further strength of our trial is our aim to monitor
program fidelity and to address the presence or absence
of critical components in the OPUS treatment. Cur-
rently, no single accepted validated standard to measure
the program fidelity of first episode psychosocial treat-
ment exists, and we hope to be able to contribute to the
establishment of such a standard.
International collaboration
The OPUS II research group has a close collaboration
with Professor Ashok Malla, Douglas Hospital Research
Centre (McGill University), Principal Investigator of the
trial ‘A randomized controlled evaluation of extended
specialized early intervention service vs. regular care for
management of early psychosis over five year critical
period’. We will ensure that the OPUS II trial and the
Canadian trial are comparable regarding intervention,
assessments tools, and other methodological questions
ensuring that the results can be meaningfully meta-
analysed.
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